Overview

Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)

Status:
Recruiting

Trial end date:
2021-07-31

Target enrollment:

Participant gender:

Summary

The main objective is to evaluate the efficacy and safety of three doses of tinzaparin (prophylactic, intermediate and therapeutic) in hospitalized patients with COVID-19 pneumonia.

Phase:

Phase 3

Details

Lead Sponsor:

Hospital Universitario Infanta Leonor

Treatments:

Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin